EA200300092A1 - Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей - Google Patents

Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей

Info

Publication number
EA200300092A1
EA200300092A1 EA200300092A EA200300092A EA200300092A1 EA 200300092 A1 EA200300092 A1 EA 200300092A1 EA 200300092 A EA200300092 A EA 200300092A EA 200300092 A EA200300092 A EA 200300092A EA 200300092 A1 EA200300092 A1 EA 200300092A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mhc class
lag
treatment
vaccination
adjuvants
Prior art date
Application number
EA200300092A
Other languages
English (en)
Inventor
Фредерик Триебель
Original Assignee
Энститю Гюстав Русси
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энститю Гюстав Русси, Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Энститю Гюстав Русси
Publication of EA200300092A1 publication Critical patent/EA200300092A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение касается использования лиганда молекул МНС класса II, такого как CD4 и LAG-3, для производства лекарственного средства, предназначенного для профилактики или лечения патологических состояний, вовлеченных в антиген-специфичный иммунный ответ, равно как и использования LAG-3 в иммунотерапии раковых заболеваний. Так же настоящее изобретение касается фармацевтической композиции, содержащей эффективное количество антигена, способного индуцировать формирование антиген-специфичного иммунного ответа наряду с эффективным количеством лиганда молекул МНС класса II, при том, что упомянутый лиганд молекул МНС класса II присутствует в качестве компонента-адъюванта.
EA200300092A 1997-07-25 1998-07-23 Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей EA200300092A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (en) 1997-07-25 1997-07-25 Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment

Publications (1)

Publication Number Publication Date
EA200300092A1 true EA200300092A1 (ru) 2003-06-26

Family

ID=8229825

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200300092A EA200300092A1 (ru) 1997-07-25 1998-07-23 Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
EA200000161A EA003740B1 (ru) 1997-07-25 1998-07-23 Применение лиганда мнс класса ii, представляющего собой lag-3 или производное, мутантную форму или растворимый фрагмент lag-3, для приготовления иммунотерапевтического лекарственного средства
EA200200565A EA005405B1 (ru) 1997-07-25 1998-07-23 Применение опухолевых клеток, трансфицированных днк, кодирующей lag-3 или cd4, для производства лекарственного препарата для профилактики или лечения злокачественных опухолей

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA200000161A EA003740B1 (ru) 1997-07-25 1998-07-23 Применение лиганда мнс класса ii, представляющего собой lag-3 или производное, мутантную форму или растворимый фрагмент lag-3, для приготовления иммунотерапевтического лекарственного средства
EA200200565A EA005405B1 (ru) 1997-07-25 1998-07-23 Применение опухолевых клеток, трансфицированных днк, кодирующей lag-3 или cd4, для производства лекарственного препарата для профилактики или лечения злокачественных опухолей

Country Status (20)

Country Link
US (2) US6410509B1 (ru)
EP (3) EP0893507A1 (ru)
JP (1) JP4723722B2 (ru)
KR (1) KR100603075B1 (ru)
CN (1) CN1184320C (ru)
AT (2) ATE324455T1 (ru)
AU (1) AU753738B2 (ru)
BR (1) BR9811037A (ru)
CA (2) CA2732570C (ru)
DE (2) DE69834330T2 (ru)
DK (1) DK1002108T3 (ru)
EA (3) EA200300092A1 (ru)
EE (1) EE200000039A (ru)
ES (1) ES2262242T3 (ru)
HK (1) HK1030014A1 (ru)
IL (2) IL134212A0 (ru)
NO (1) NO20000378D0 (ru)
PT (1) PT1002108E (ru)
UA (1) UA75322C2 (ru)
WO (1) WO1999004810A2 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519779T1 (de) * 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
ES2439580T3 (es) 2003-02-28 2014-01-23 The Johns Hopkins University Regulación de células T
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
PL2638062T3 (pl) 2010-11-10 2018-11-30 Laboratorios Leti, S.L. Nowy adiuwant
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
KR20220126813A (ko) 2014-03-14 2022-09-16 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
WO2016094639A1 (en) * 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
EP3269733B1 (en) 2015-03-09 2020-06-17 Cytlimic Inc. Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
WO2016163489A1 (ja) 2015-04-07 2016-10-13 日本電気株式会社 医薬
CN107847572A (zh) 2015-05-13 2018-03-27 艾吉纳斯公司 用于癌症治疗和预防的疫苗
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
BR112019006075A2 (pt) 2016-10-11 2019-06-18 Cytlimic Inc medicamento
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
BR112021005221A2 (pt) * 2018-09-27 2021-06-15 Genocea Biosciences Inc. métodos de tratamento
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
EP0385909B1 (en) * 1989-03-03 1994-07-13 MicroGeneSys, Inc. A kit or composition for the prevention or treatment of HIV-1 infections
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
NZ262582A (en) * 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
IL113617A (en) * 1994-05-06 2007-09-20 Florence Faure Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system
EP0774003A1 (en) * 1994-08-05 1997-05-21 Warner-Lambert Company Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
CZ172497A3 (en) * 1994-12-07 1997-10-15 Hoffmann La Roche Fragments of monoclonal substance exhibiting immunosuppressor activity
PL320922A1 (en) * 1994-12-23 1997-11-10 Om Lab Sa Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
ATE237338T1 (de) * 1995-12-28 2003-05-15 Univ Johns Hopkins Med Allogene parakrine cytokine tumor impfstoffe

Also Published As

Publication number Publication date
CA2732570C (en) 2014-11-18
EP1002108A2 (en) 2000-05-24
WO1999004810A3 (en) 1999-07-08
US20020192195A1 (en) 2002-12-19
EA200200565A1 (ru) 2002-10-31
EA005405B1 (ru) 2005-02-24
HK1030014A1 (en) 2001-04-20
ATE478956T1 (de) 2010-09-15
DK1002108T3 (da) 2006-08-21
NO20000378L (no) 2000-01-25
US7109026B2 (en) 2006-09-19
CA2293805A1 (en) 1999-02-04
CN1265149A (zh) 2000-08-30
US6410509B1 (en) 2002-06-25
UA75322C2 (en) 2006-04-17
KR100603075B1 (ko) 2006-07-20
EP1002108B1 (en) 2006-04-26
EP1698701A1 (en) 2006-09-06
IL134212A0 (en) 2001-04-30
PT1002108E (pt) 2006-09-29
BR9811037A (pt) 2000-08-01
AU753738B2 (en) 2002-10-24
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (en) 1999-01-27
KR20010021706A (ko) 2001-03-15
CA2732570A1 (en) 1999-02-04
DE69834330D1 (de) 2006-06-01
CN1184320C (zh) 2005-01-12
ES2262242T3 (es) 2006-11-16
NO20000378D0 (no) 2000-01-25
DE69834330T2 (de) 2007-03-29
EA003740B1 (ru) 2003-08-28
EE200000039A (et) 2000-10-16
DE69841866D1 (de) 2010-10-07
IL134212A (en) 2012-03-29
JP4723722B2 (ja) 2011-07-13
ATE324455T1 (de) 2006-05-15
AU9254798A (en) 1999-02-16
CA2293805C (en) 2011-05-03
EP1698701B1 (en) 2010-08-25
JP2001510806A (ja) 2001-08-07
WO1999004810A2 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
EA200300092A1 (ru) Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
Garbe et al. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
HUP0301727A2 (hu) Eljárás reumatoid artritisz kezelésére oldható mutáns CTLA4 molekula alkalmazásával
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
BR0015597A (pt) Uso de anticorpos como vacinas
DK0522078T3 (da) GP75 som en tumorvaccine mod melanom
EA200701071A1 (ru) Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
MY195821A (en) Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers
RU93004625A (ru) Способы лечения, противоопухолевые агенты
Calman et al. Immunotherapy
Gattoni-Celli Tumor Immunology
TH59159B (th) สารรวมที่ใช้รักษาภูมิคุ้มกันสำหรับการบำบัดรักษาเนื้องอกที่แสดงแกงกลิโอไซด์ที่มากเกินไป
TH83896A (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2 เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง